Program
entecavir
Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.
Drug pageEntecavir: every studyMany companies study it; this page follows only the 32 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 240 open or running | phase 4since Aug 29, 2006 | May 4, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 40 open or running | phase 4since Jan 30, 2008 | Jan 30, 2008 | none ahead |
| Ascentage Pharma Group Internationalits history only | 11 open or running | phase 2since Sep 24, 2020 | Sep 24, 2020 | none ahead |
| Aucta Pharmaceuticalsits history only | 10 open or running | phase 1since Jul 27, 2017 | Jul 27, 2017 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 4since Jul 26, 2015 | Jul 26, 2015 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | no phasesince Jan 22, 2019 | Jan 22, 2019 | none ahead |
Also a collaborator on its studies: ICON Clinical Research and CPR Pharma Services Pty Ltd, Australia.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since May 4, 2002.
- Sep 8, 2009Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT00975091 · 600 enrolled
- Sep 29, 2009Phase 4 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT00986778
- Nov 24, 20092 phase 2 studies in Hepatitis B, ChronicBristol-Myers Squibb · NCT01020565, NCT01022801
- Dec 17, 20092 phase 2 studies in Hepatitis B, ChronicBristol-Myers Squibb · NCT01037166, NCT01037062
- Feb 3, 2010Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT01063036 · 144 enrolled · France, Germany, Italy and more
- Mar 2, 2010Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT01079806 · 180 enrolled · United States, Argentina, Belgium and more
- Aug 10, 2010Phase 4 study in Hepatitis B, ChronicHoffmann-La Roche · NCT01179594
- Sep 16, 2011Phase 2 study in Hepatitis BBristol-Myers Squibb · NCT01438424 · 1,053 enrolled
- Oct 2, 2014Phase 3 study in Pediatric Immuno-Tolerant Chronic Hepatitis BHoffmann-La Roche · NCT02263079 · 62 enrolled · United States, Australia, Belgium and more
- Jul 26, 2015Hanmi Pharmaceutical’s first study: phase 4 study in Hepatitis B, ChronicNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02523547 · 134 enrolled · Korea, Republic of
- Mar 14, 2017Phase 1 study in Hepatitis BBristol-Myers Squibb · NCT03083821 · 6 enrolled · Japan
- Jul 27, 2017Aucta Pharmaceuticals’ first study: phase 1 study in HBVNew to Aucta PharmaceuticalsAucta Pharmaceuticals · NCT03239353 · 40 enrolled · Australia
- Jan 22, 2019Sino Biopharmaceutical’s first study: no phase study in Hepatitis B, ChronicNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03847246 · 26 enrolled · China
- Sep 24, 2020Ascentage Pharma Group International’s first study: phase 2 study in Hepatitis BNew to Ascentage Pharma Group InternationalAscentage Pharma Group International · NCT04568265 · 122 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04568265Hepatitis B · China | 2 | Recruiting | Ascentage Pharma Group International | Oct 31, 2022 | 122 |
| NCT03847246Hepatitis B, Chronic · China | – | Completed | Sino Biopharmaceutical | Dec 28, 2018 | 26 |
| NCT03239353HBV · Australia | 1 | Completed | Aucta Pharmaceuticals | May 29, 2018 | 40 |
| NCT03083821Hepatitis B · Japan | 1 | Completed | Bristol-Myers Squibb | Dec 19, 2017 | 6 |
| NCT02523547Hepatitis B, Chronic · Korea, Republic of | 4 | UNKNOWN | Hanmi Pharmaceutical | Feb 2017 | 134 |
| NCT02263079Pediatric Immuno-Tolerant Chronic Hepatitis B · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jan 29, 2020 | 62 |
| NCT01438424Hepatitis B | 2 | Completed | Bristol-Myers Squibb | Dec 2009 | 1,053 |
| NCT01179594Hepatitis B, Chronic | 4 | Withdrawn | Hoffmann-La Roche | Nov 2014 | 0 |
| NCT01079806Hepatitis B, Chronic · United States, Argentina, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Mar 31, 2013 | 180 |
| NCT01063036Hepatitis B, Chronic · France, Germany, Italy and more | 3 | Completed | Bristol-Myers Squibb | Nov 2012 | 144 |
| NCT01037166Hepatitis B, Chronic · Japan | 2 | Completed | Bristol-Myers Squibb | Feb 2005 | 84 |
| NCT01037062Hepatitis B, Chronic · Japan | 2 | Completed | Bristol-Myers Squibb | Dec 2006 | 282 |
| NCT01022801Hepatitis B, Chronic | 2 | Completed | Bristol-Myers Squibb | Mar 2005 | 120 |
| NCT01020565Hepatitis B, Chronic | 2 | Completed | Bristol-Myers Squibb | Feb 2005 | 60 |
| NCT00986778Hepatitis B, Chronic | 4 | Withdrawn | Bristol-Myers Squibb | Dec 2012 | 0 |
| NCT00975091Hepatitis B, Chronic | 3 | Completed | Bristol-Myers Squibb | Aug 2007 | 600 |
| NCT00922207Hepatitis B, Chronic · Taiwan | 4 | Completed | Hoffmann-La Roche | Sep 29, 2014 | 280 |
| NCT00718887Hepatitis B, Chronic · China | 4 | Completed | Bristol-Myers Squibb | Dec 2009 | 228 |
| NCT00614471Hepatitis B, Chronic · China, Hong Kong | 4 | Completed | Hoffmann-La Roche | Oct 2009 | 219 |
| NCT00605384Hepatitis B, Chronic · United States, Belgium, Germany and more | 3 | Terminated | Bristol-Myers Squibb | Feb 2009 | 4 |
| NCT00423891Hepatitis B, Chronic · United States, Argentina, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Aug 31, 2013 | 64 |
| NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jan 2011 | 629 |
| NCT00410072Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Oct 2010 | 669 |
| NCT00395018Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Mar 2011 | 109 |
| NCT00393484Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Bristol-Myers Squibb | Jan 2009 | 122 |
| NCT00371150Hepatitis B · United States, Brazil, Mexico and more | 4 | Completed | Bristol-Myers Squibb | Mar 2011 | 131 |
| NCT00096785Hepatitis B · United States, Canada, Hong Kong and more | 3 | Completed | Bristol-Myers Squibb | Jan 2006 | 69 |
| NCT00065507Hepatitis B · United States, Brazil, Canada and more | 3 | Completed | Bristol-Myers Squibb | Oct 2008 | 195 |
| NCT00051038Hepatitis B · United States | 3 | Completed | Bristol-Myers Squibb | Oct 2005 | |
| NCT00036608Hepatitis B, Chronic · United States | 3 | Completed | Bristol-Myers Squibb | Feb 2005 | |
| NCT00035789Hepatitis B, Chronic · United States | 3 | Completed | Bristol-Myers Squibb | May 2005 | |
| NCT00035633Hepatitis B, Chronic · United States | 3 | Completed | Bristol-Myers Squibb | Feb 2005 |
How it is read
Names in the registry
- “Entecavir”, 28 entries
- “entecavir”, 4 entries
- “Entecavir (ETV)”, 2 entries
- “Entecavir + Tenofovir”, 2 entries
- “P1101 + Nivolumab + Entecavir”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 34 studies
- Hepatitis B, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.